Aclarion Q1 Scan Volumes Jump 196% as $2.5M Buyback Boosts Cash Position
Aclarion reported Q1 2026 scan volumes for Nociscan surged 196% year-over-year and 64% sequentially, driven by new account activations and deeper utilization. The company holds $19M cash, no debt, initiated a $2.5M buyback and strengthened its IP portfolio to 64 patents, with CLARITY trial interim readout due Q4 2026.
1. Robust Volume Growth
Aclarion’s Nociscan platform recorded a 196% year-over-year increase in scan volumes in Q1 2026, with a 64% sequential rise from Q4 2025, driven by new account activations and deeper utilization within existing clinical sites.
2. Strong Financial Position
As of March 31, 2026, Aclarion held $19.0 million in cash with no debt, announced a $2.5 million share repurchase program and maintains an estimated cash runway into the second half of 2027, equivalent to roughly $6.60 per fully diluted share.
3. Strategic Milestones and IP Expansion
The company expanded its intellectual property portfolio to 64 issued and pending patents, secured early reimbursement from major UK insurers and expects an interim readout from its CLARITY randomized trial in Q4 2026 to validate clinical utility.